InBioGen Co Ltd Cash Flow-to-Debt Ratio
InBioGen Co Ltd cash flow-to-debt ratio. InBioGen Co Ltd (101140) has a Cash Flow-to-Debt Ratio of -0.68x as of September 2025, meaning its operating cash flow of ₩-1.67 Billion could theoretically repay -1% of its total liabilities (₩2.44 Billion) in one year. Check 101140 cash reinvestment to operating cash ratio to assess the company's total reinvestment commitment from operating cash flow.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of InBioGen Co Ltd (2013–2024)
Cash flow-to-debt ratio of InBioGen Co Ltd from 2013 to 2024. Historical debt coverage capacity for InBioGen Co Ltd across 12 annual periods. Check InBioGen Co Ltd earnings quality ratio to evaluate the quality of earnings relative to operating cash generation.
InBioGen Co Ltd Cash Flow-to-Debt Ratio by Year (2013–2024)
InBioGen Co Ltd cash flow-to-debt ratio by year from 2013 to 2024. Year-by-year debt coverage analysis for InBioGen Co Ltd. For the full cash flow conversion analysis, see InBioGen Co Ltd operating cash flow efficiency.
| Year | CF-to-Debt Ratio | Operating CF (KRW) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -0.01x | ₩-33.13 Million | ₩2.89 Billion | ▲ +97.1% |
| 2023 | -0.40x | ₩-1.05 Billion | ₩2.62 Billion | ▼ -30.3% |
| 2022 | -0.31x | ₩-11.51 Billion | ₩37.40 Billion | ▼ -319.7% |
| 2021 | -0.07x | ₩-7.07 Billion | ₩96.45 Billion | ▲ +82.7% |
| 2020 | -0.42x | ₩-8.03 Billion | ₩18.97 Billion | ▼ -175.6% |
| 2019 | -0.15x | ₩-3.83 Billion | ₩24.92 Billion | ▲ +91.2% |
| 2018 | -1.75x | ₩-1.70 Billion | ₩968.80 Million | ▼ -749.2% |
| 2017 | -0.21x | ₩-426.44 Million | ₩2.07 Billion | ▼ -496.8% |
| 2016 | 0.05x | ₩344.75 Million | ₩6.62 Billion | ▲ +103.2% |
| 2015 | -1.62x | ₩-10.96 Billion | ₩6.76 Billion | ▼ -595.5% |
| 2014 | -0.23x | ₩-695.95 Million | ₩2.99 Billion | ▼ -30.4% |
| 2013 | -0.18x | ₩-1.13 Billion | ₩6.33 Billion | — |